Rezield Needs Advantage Over Synagis, Advisory Cmte. Tells MedImmune

If MedImmune wants to move forward with Rezield (motavizumab), its preventive treatment for respiratory syncytial virus disease, it will likely have to demonstrate some advantage over its currently approved product, Synagis (palivizumab)